Nephrol Dial Transplant (2003) 18: 370-377
© 2003 European Renal Association-European Dialysis and Transplant Association
Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients
1 Faculty of Medicine and 2 Department of Biochemistry and Center for Cellular and Molecular Biology, National Yang-Ming University School of Medicine, 3 Division of Nephrology, Department of Medicine and 4 Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
Background. Optimal response to recombinant human erythropoietin (rHuEpo) in haemodialysis (HD) patients requires provision of sufficient available iron. However, a balance between iron requirements and supplements remains a challenge in clinical practice. Reticulocyte parameters, i.e. reticulocyte haemoglobin content (CHr) and reticulocytes in a high-fluorescence intensity region (HFR), have been shown to be accurate predictors of iron-deficient erythropoiesis as compared with traditional markers. Therefore, the aim of this study was to appraise the diagnostic power of these two parameters in the early prediction of response to intravenous iron (IVFE) medications in HD patients receiving rHuEpo.
Methods. Sixty-five HD patients with a serum ferritin level of <500 µg/l and on rHuEpo therapy for >6 months were enrolled for IVFE supplementation (100 mg iron saccharate three times a week for 4 weeks, then 100 mg every 2 weeks for 5 months). Haemoglobin, haematocrit, serum ferritin, transferrin saturation, reticulocyte count, percentage of hypochromic red cells, CHr and HFR were measured before and following iron supplementation. Response was defined as a rise in haematocrit of >3% and/or a reduction in rHuEpo dose of >30% over the baseline values at the end of the study.
Results. Forty-two patients had a dramatic response to IVFE therapy with a 13.5% increase in mean haematocrit and a 38% reduction in rHuEpo dose at the end of the study (P<0.001). This paralleled a statistically significant rise in CHr and HFR (P<0.001). Univariate analyses showed that ferritin (P<0.010) and CHr (P<0.001) at baseline, changes in CHr (
CHr2W, P<0.001) and HFR (HFR2W, P<0.010) at 2 weeks, as well as changes in CHr (CHr4W, P<0.001) and HFR (HFR4W, P<0.001) at 4 weeks, strongly correlated with response to IVFE supplementation. Stepwise discriminant analysis disclosed that CHr4W in conjunction with HFR4W exhibited an r2 value of 0.531 (P<0.001) to predict response to IVFE therapy. Analyses by receiver operating characteristic curves and logistic regression further revealed that CHr4W at a cut-off value of >1.2 pg and HFR4W of >500/µl were more specific to the status of iron-deficient erythropoiesis following IVFE medications. Combined use of the two cut-off values allowed for the highest accuracy in the early prediction of the response to IVFE therapy, with a sensitivity of 96% and a specificity of 100%.
Conclusions. Our study shows that changes in CHr and HFR at either 2 or 4 weeks are superior to the conventional erythrocyte and iron metabolism indices and may serve as reliable parameters to detect iron-deficient erythropoiesis in HD patients undergoing rHuEpo therapy. During aggressive IVFE treatment, early identification of non-responsiveness and subsequent discontinuation of treatment can avoid the inadvertent iron-related toxicity due to over-treatment.
Keywords: functional iron deficiency; haemodialysis; high-fluorescence reticulocyte; intravenous iron therapy; recombinant human erythropoietin; reticulocyte haemoglobin content
Correspondence and offprint requests to: Der-Cherng Tarng, MD, PhD, Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan. Email: dctarng{at}vghtpe.gov.tw
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. S Shord, J.M. Hamilton Jr, and S. Cuellar Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia Journal of Oncology Pharmacy Practice, March 1, 2008; 14(1): 5 - 22. [Abstract] [PDF]
|
|
|
|
 |
|
 D. W. Coyne, T. Kapoian, W. Suki, A. K. Singh, J. E. Moran, N. V. Dahl, A. R. Rizkala, and the DRIVE Study Group Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study J. Am. Soc. Nephrol., March 1, 2007; 18(3): 975 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Horl Clinical Aspects of Iron Use in the Anemia of Kidney Disease J. Am. Soc. Nephrol., February 1, 2007; 18(2): 382 - 393. [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Coyne Practice Recommendations Based on Low, Very Low, and Missing Evidence Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 11 - 12. [Full Text] [PDF]
|
|
|
|
|
|
A. Besarab More than a Decade of Experience and Still No Consensus: Controversies in Iron Therapy Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(Supplement_1): S1 - S3. [Full Text] [PDF]
|
|
|
|
|
|
J. B. Wish Assessing Iron Status: Beyond Serum Ferritin and Transferrin Saturation Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(Supplement_1): S4 - S8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Brugnara Iron Deficiency and Erythropoiesis: New Diagnostic Approaches Clin. Chem., October 1, 2003; 49(10): 1573 - 1578. [Abstract] [Full Text] [PDF]
|
|